The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
Amna Zafar(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Hannah Gilman(Massachusetts General Hospital), Colin D. Weekes(Massachusetts General Hospital), Uvette Lou(Harvard University), Matthew Lei(Massachusetts General Hospital), Sean Murphy(Massachusetts General Hospital), Zsófia D. Drobni(Semmelweis University), Vineet K. Raghu(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), John R. Clark(Harvard University), Erica Tavares(University of California, San Francisco), Raza M. Alvi(Massachusetts General Hospital), Ramya Mosarla(Harvard University), Sarah Hartmann(Massachusetts General Hospital), Maeve Jones‐O’Connor(Harvard University)
Cited by 74
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k